Sale on Ophthalmic Equipment - Starting from 16 November!
GeneDx has appointed Everett Cunningham, formerly of Quanterix, as CEO to replace Katherine Stueland, and analysts weigh in on both companies.
The GeneDx CEO appointment is official. GeneDx, a genetic testing company, said Everett Cunningham will become chief executive on or before 15 December. He replaces Katherine Stueland, who has led the company since 2021.
GeneDx made the announcement on Wednesday. Stueland will leave the CEO role and the board when Cunningham arrives. She will stay on as an adviser until 31 January to ease the handover. Cunningham joins from Quanterix, where he was CEO. Earlier in his career he held leadership roles at Illumina, Exact Sciences, GE HealthCare and Quest Diagnostics.
Analysts at TD Cowen said GeneDx sales have nearly tripled since Stueland became CEO. They also said performance has "been more uneven" in recent quarters. In their view, pricing gains slowed and testing moved faster towards whole genome tests that earn lower margins. They added that the leadership change would probably not surprise the market.
The same analysts said his experience could help GeneDx improve revenue cycle management, enter new markets and keep its lead in a crowded field. They singled out his time at Exact Sciences, where primary care providers are a core channel. They estimate that channel covers nearly two thirds of the rare and undiagnosed genetic disease opportunity open to GeneDx. They also warned it is a new route to customers, likely with very different traits from its main specialist route. The GeneDx CEO appointment therefore carries a test of commercial reach.
Leerink Partners analysts said Cunningham's "abrupt exit" raises questions about Quanterix's diagnostic pivot. Quanterix named him CEO in January. Chief commercial officer Jim Gute will act as interim CEO. Analysts at Canaccord Genuity said his Exact Sciences background should help as the company focuses on neurology diagnostics. Quanterix has started a search that covers both internal and outside candidates.
The GeneDx CEO appointment shows how closely investors watch leadership in genetic testing, where pricing and test mix are shifting. Medigear.uk helps clinical buyers compare verified suppliers. Leadership news of this kind does not change product availability for UK buyers. The views here belong to the analysts quoted.
Source: MedTech Dive
Tell us the model and destination — our sourcing team will respond within one business day.

The Zimmer Monogram robot is now with US regulators. Zimmer Biomet has filed a 510(k) submission for…

The Abbott Encantor trial has begun. Abbott said on Thursday that it has started the VOYAGER CE clin…

Johnson & Johnson (J&J) said on Thursday that a Houston hospital will be the first to instal…
Approvals, trials, recalls and market moves — the essentials for procurement and clinical teams.